Deborah Morosini

All filings by Deborah Morosini on record concern Prelude Therapeutics Inc, in the capacity of chief executive. Between 29 September 2020 and 15 December 2021, the trades on record add up to 13 filings.

On the open market, the record shows 1 purchase worth €7,184 and 6 sales worth €878k. Sales outweigh purchases by €870k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 6 option exercises. 2021 to date brings no purchases and 6 sales.

On 17 December 2021 came the latest disclosure, an option exercise for €294k in Prelude Therapeutics Inc. The clock since the last published purchase (29 September 2020) now reads 2,232 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.